ARTL vs FRT · $15.6M cap vs rev $1.28B
Artelo Biosciences Inc (ARTL) versus FRT (FRT) — a side-by-side from cached financials, not a winner call.
Artelo Biosciences Inc (ARTL) is a biotechnology company listed on US.
FRT (FRT) common stock.
ARTL does not have a complete income-statement cache yet.
Latest reported FRT revenue for 2025-12-31 was $1.28B. Net income was $411.1M. Revenue was up 6.4% from 2024-12-31 to 2025-12-31. FRT currently screens at market cap $0.
ARTL currently screens at market cap $15.6M. FRT currently screens at market cap $0.
Not investment advice. Open the ARTL and FRT stock pages for the full models.
Not investment advice.